Significance of the TMPRSS2:ERG gene fusion in prostate cancer

被引:80
作者
Wang, Zhu [1 ,2 ]
Wang, Yuliang [3 ]
Zhang, Jianwen [1 ,2 ]
Hu, Qiyi [1 ,2 ]
Zhi, Fan [1 ,2 ]
Zhang, Shengping [1 ,2 ]
Zhang, Ying [1 ,2 ]
Liang, Hui [1 ,2 ]
机构
[1] Southern Med Univ, Dept Urol, Peoples Hosp Longhua New Dist Shenzhen, 38 Jianshe Rd,Longhua St, Shenzhen 518109, Guangdong, Peoples R China
[2] Southern Med Univ, Affiliated Shenzhen Longhua Hosp, 38 Jianshe Rd,Longhua St, Shenzhen 518109, Guangdong, Peoples R China
[3] Peking Univ, Dept Urol, Peoples Hosp, Beijing 100044, Peoples R China
关键词
prostate cancer; transmembrane protease serine 2; v-ets erythroblastosis virus E26 oncogene homolog; fusion gene; bioinformatics; ERG EXPRESSION; IDENTIFICATION; STATISTICS;
D O I
10.3892/mmr.2017.7281
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The transmembrane protease serine 2:v-ets erythroblastosis virus E26 oncogene homolog (TMPRSS2:ERG) gene fusion is common in prostate cancer, while its functional role is not fully understood. The present study aimed to investigate the significance of the TMPRSS2:ERG gene fusion in human prostate cancers using bioinformatics tools. Comprehensive alteration analysis of TMPRSS2 and ERG in 148 different human cancer studies was performed by cBioPortal, and the mRNA expression level of the ERG gene was evaluated using Oncomine analysis. Furthermore, lentiviral short hairpin (sh)RNA-mediated knockdown of TMPRSS2:ERG was performed to study the impact of ERG silencing on cell proliferation and cell cycle distribution in prostate cancer cells. The results demonstrated that the TMPRSS2 and ERG genes were mostly altered in prostate cancer, and the most frequent alteration was gene fusion. Oncomine analysis demonstrated that the ERG gene was significantly upregulated in prostate clinical samples compared with the normal prostate gland in four independent datasets, and a positive association was observed between potassium inwardly-rectifying channel subfamily J member 15, down syndrome critical region gene 4, potassium inwardly-rectifying channel subfamily J member 6 and ERG gene expression. There were 272 mutations of the ERG gene identified in the cBioPortal database; among the mutations, 2 missense mutations (R367C and P401H) were regarded as functional mutations (functional impact score > 1.938). Furthermore, the present study successfully knocked down ERG gene expression through a lentiviral-mediated gene silencing approach in VCaP prostate cancer cells. The ERG mRNA and protein expression levels were both suppressed significantly, and a cell-cycle arrest at G(0)/G(1) phase was observed after ERG gene silencing. In conclusion, these bioinformatics analyses provide novel insights for TMPRSS2:ERG fusion gene study in prostate cancer. Target inhibition of ERG expression could significantly cause cell growth arrest in prostate cancer cells, which could be a potentially valuable target for prostate cancer treatment. However, the precise mechanism of these results remains unclear; therefore, further studies are required.
引用
收藏
页码:5450 / 5458
页数:9
相关论文
共 50 条
  • [21] TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases
    Delliaux, Carine
    Tian, Tian, V
    Bouchet, Mathilde
    Fradet, Anais
    Vanpouille, Nathalie
    Flourens, Anne
    Deplus, Rachel
    Villers, Arnauld
    Leroy, Xavier
    Clezardin, Philippe
    de Launoit, Yvan
    Bonnelye, Edith
    Duterque-Coquillaud, Martine
    CANCER LETTERS, 2018, 438 : 32 - 43
  • [22] The oncogenic gene fusion TMPRSS2: ERG is not a diagnostic or prognostic marker for ovarian cancer
    Huang, Lillian
    Schauer, Isaiah G.
    Zhang, Jing
    Mercado-Uribe, Imelda
    Deavers, Michael T.
    Huang, Jiaoti
    Liu, Jinsong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2011, 4 (07): : 644 - 650
  • [23] Bioinformatics approach leads to the discovery of the TMPRSS2: ETS gene fusion in prostate cancer
    Rubin, Mark A.
    Chinnaiyan, Arul M.
    LABORATORY INVESTIGATION, 2006, 86 (11) : 1099 - 1102
  • [24] Whole-transcriptome Analysis Reveals Established and Novel Associations with TMPRSS2:ERG Fusion in Prostate Cancer
    Chow, Anthony
    Amemiya, Yutaka
    Sugar, Linda
    Nam, Robert
    Seth, Arun
    ANTICANCER RESEARCH, 2012, 32 (09) : 3629 - 3641
  • [25] Exploring therapeutic applications of PTEN, TMPRSS2:ERG fusion, and tumour molecular subtypes in prostate cancer management
    Bugoye, Fidelis Charles
    Torrorey-Sawe, Rispah
    Biegon, Richard
    Dharsee, Nazima
    Mafumiko, Fidelice
    Kibona, Herry
    Aboud, Said
    Patel, Kirtika
    Mining, Simeon
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [26] miR-221 Is Down-regulated in TMPRSS2:ERG Fusion-positive Prostate Cancer
    Gordanpour, Aida
    Stanimirovic, Aleksandra
    Nam, Robert K.
    Moreno, Carlos S.
    Sherman, Christopher
    Sugar, Linda
    Seth, Arun
    ANTICANCER RESEARCH, 2011, 31 (02) : 403 - 410
  • [27] A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis
    Lapointe, Jacques
    Kim, Young H.
    Miller, Melinda A.
    Li, Chunde
    Kaygusuz, Gulsah
    van de Rijn, Matt
    Huntsman, David G.
    Brooks, James D.
    Pollack, Jonathan R.
    MODERN PATHOLOGY, 2007, 20 (04) : 467 - 473
  • [28] Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions
    Stopsack, Konrad H.
    Su, Xiaofeng A.
    Vaselkiv, J. Bailey
    Graff, Rebecca E.
    Ebot, Ericka M.
    Pettersson, Andreas
    Lis, Rosina T.
    Fiorentino, Michelangelo
    Loda, Massimo
    Penney, Kathryn L.
    Lotan, Tamara L.
    Mucci, Lorelei A.
    MOLECULAR CANCER RESEARCH, 2023, 21 (01) : 14 - 23
  • [29] Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG
    Graff, Rebecca E.
    Judson, Gregory
    Ahearn, Thomas U.
    Fiorentino, Michelangelo
    Loda, Massimo
    Giovannucci, Edward L.
    Mucci, Lorelei A.
    Pettersson, Andreas
    PROSTATE, 2017, 77 (06) : 647 - 653
  • [30] TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer
    Zoran Krstanoski
    Nadja Kokalj Vokac
    Andreja Zagorac
    Boris Pospihalj
    Miha Munda
    Saso Dzeroski
    Rastko Golouh
    BMC Urology, 16